Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies!

The bi-specific MAbs market is forecasted to achieve exponential growth in the coming few years with a forecast CAGR (compound annual growth rate) of more than 22%, as per The Business Research Company’s market report!

Read More On The Bi-Specific MAbs Market Report 2022 – https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

The Bi-Specific MAbs Market Size In 2022 And Forecast
The global bi-specific MAbs market is expected to grow from $3.80 billion in 2021 to $5.13 billion in 2022 at a compound annual growth rate (CAGR) of 34.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The bi-specific MAbs or bispecific monoclonal antibodies market is expected to reach $11.64 billion in 2026 at a CAGR of 22.7%.

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services.

Request for A Sample Of The Global Bi-Specific MAbs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Increase In Prevalence Of Cancer And Other Chronic Diseases Is Driving The Growth Of The Bi-Specific MAbs Market
According to the World Health Organization, cancer is the leading cause of death worldwide and is responsible for around 10 million deaths in 2020. Additionally, according to the Centers for Disease Control and Prevention, chronic diseases are among the most prevalent diseases with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases including cancer is anticipated to propel the demand for bi-specific MAbs market to treat these diseases effectively.

Competitive Landscape And The Regional Analysis Of The Bi-Specific MAbs Market
Major players in the bi-specific MAbs market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company Ltd. and Abbott.

The Bi-Specific MAbs Global Market Report 2022 covers regional data on key drivers, opportunities, and strategies for the seven major regions of the world that are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bi-specific MAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The report includes market size and forecast market shares for all the regions and countries with respect to the major players of the bi-specific MAbs market.

Strategic Collaboration – A Key Trend In The Bi-Specific MAbs Market
Companies in the bi-specific MAbs market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company.

Bi-Specific MAbs Market Segmentation By The Business Research Company
1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Others
4) By End Use: Hospitals, Research Institutes, Others

Here Are Some Reports Related To The Bi-Specific MAbs Market –
Monoclonal Antibodies (MAbs) Global Market Report 2022
Biosimilar Monoclonal Antibodies Global Market Report 2022
Conjugated Monoclonal Antibodies Global Market Report 2022

Get In Touch With Us – Call us at:
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Found This Article Helpful? Share It On: